Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda Pharmaceutical paid $196 million up front to acquire Ovid’s rights to a Phase 3 ready molecule for two rare forms of epilepsy.